Menu
Recruiting NCT03826693

Efficacy of Nitrous Oxide in OCD: Pilot Study

Phase II Interventional Obsessive-Compulsive Disorder

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Nitrous Oxide, Nitrogen.
Who it may be relevant to
Registry conditions: Obsessive-Compulsive Disorder. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This study investigates whether the commonly used and well-tolerated inhaled anesthetic nitrous oxide can rapidly improve symptoms of OCD.

Detailed description

Obsessive-compulsive disorder (OCD) is a chronic and disabling disorder characterized by recurrent intrusive thoughts and associated compulsive behaviors that is estimated to affect more than 3 million individuals in the US each year.

This study seeks to explore whether a single inhalation of nitrous oxide gas may bring about rapid symptom relief in OCD.

Interventions

  • Drug Nitrous Oxide
    OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
  • Drug Nitrogen
    OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.

Primary outcome measures

  • Improvement in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS) [Time frame: 1 week]

Eligibility criteria

Inclusion criteria

  • Age 18-65
  • Primary diagnosis of OCD
  • Sufficient severity of OCD symptoms
  • Ability to tolerate a treatment-free period
  • Capacity to provide informed consent

Exclusion criteria

  • Psychiatric or medical conditions that make participation unsafe
  • Pregnant or nursing females
  • Concurrent use of any medications that might increase the risk of participation (e.g. drug interactions)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • Stanford University — Stanford

Identifiers

NCT: NCT03826693 · 48077

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗